Literature DB >> 12573277

Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis.

C A Glader1, L S Birgander, S Söderberg, H P Ildgruben, P Saikku, A Waldenström, G H Dahlén.   

Abstract

AIMS: The aim of the present study was to identify risk markers for the development of valvular aortic stenosis (AS). Lipoprotein(a) (Lp(a)) and Chlamydia pneumoniae IgG antibody titres in plasma and in circulating immune complexes as well as leptin and tissue plasminogen activator (t-PA) in plasma were studied. METHODS AND
RESULTS: One hundred and one patients (41 women and 60 men, mean age 71+/-8 years) with significant AS and 101 age- and sex-matched controls were included in this study. All patients underwent aortic valve replacement at the University Hospital in Umeå, Sweden. The controls had no symptoms of cardiovascular disease and they were examined echocardiographically. An Lp(a) level >or=480 mg x l(-1), a C. pneumoniae-specific IgG titre >or=1/128, a high leptin level and a high t-PA mass concentration in plasma were identified as risk markers for AS. A strong synergism between Lp(a) and C. pneumoniae IgG antibodies in circulating immune complexes was found.
CONCLUSION: Our data indicate that a chronic C. pneumoniae infection and a high plasma Lp(a) level might influence and aggravate aortic heart valve sclerosis via the formation of circulating immune complexes. The present study also strongly suggests an association between high plasma leptin, t-PA mass concentration and AS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12573277     DOI: 10.1016/s0195-668x(02)00385-8

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  27 in total

Review 1.  Degenerative aortic stenosis.

Authors:  Radhakrishnan Ramaraj; Vincent L Sorrell
Journal:  BMJ       Date:  2008-03-08

Review 2.  Lp(a): Addressing a Target for Cardiovascular Disease Prevention.

Authors:  Nestor Vasquez; Parag H Joshi
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

Review 3.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

Review 4.  Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis.

Authors:  George Thanassoulis
Journal:  J Lipid Res       Date:  2015-12-18       Impact factor: 5.922

Review 5.  Insights into the use of biomarkers in calcific aortic valve disease.

Authors:  Erik Beckmann; Juan B Grau; Rachana Sainger; Paolo Poggio; Giovanni Ferrari
Journal:  J Heart Valve Dis       Date:  2010-07

Review 6.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Authors:  Calvin Yeang; Michael J Wilkinson; Sotirios Tsimikas
Journal:  Curr Opin Cardiol       Date:  2016-07       Impact factor: 2.161

Review 7.  Vascular Imaging Before Transcatheter Aortic Valve Replacement (TAVR): Why and How?

Authors:  Damiano Caruso; Russell D Rosenberg; Carlo N De Cecco; Stefanie Mangold; Julian L Wichmann; Akos Varga-Szemes; Daniel H Steinberg; Andrea Laghi; U Joseph Schoepf
Journal:  Curr Cardiol Rep       Date:  2016-02       Impact factor: 2.931

Review 8.  Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy.

Authors:  Anne Langsted; Børge G Nordestgaard
Journal:  Curr Atheroscler Rep       Date:  2021-06-20       Impact factor: 5.113

9.  Genetic associations with valvular calcification and aortic stenosis.

Authors:  George Thanassoulis; Catherine Y Campbell; David S Owens; J Gustav Smith; Albert V Smith; Gina M Peloso; Kathleen F Kerr; Sonali Pechlivanis; Matthew J Budoff; Tamara B Harris; Rajeev Malhotra; Kevin D O'Brien; Pia R Kamstrup; Børge G Nordestgaard; Anne Tybjaerg-Hansen; Matthew A Allison; Thor Aspelund; Michael H Criqui; Susan R Heckbert; Shih-Jen Hwang; Yongmei Liu; Marketa Sjogren; Jesper van der Pals; Hagen Kälsch; Thomas W Mühleisen; Markus M Nöthen; L Adrienne Cupples; Muriel Caslake; Emanuele Di Angelantonio; John Danesh; Jerome I Rotter; Sigurdur Sigurdsson; Quenna Wong; Raimund Erbel; Sekar Kathiresan; Olle Melander; Vilmundur Gudnason; Christopher J O'Donnell; Wendy S Post
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

Review 10.  Lipoprotein (a): Recent Updates on a Unique Lipoprotein.

Authors:  Anum Saeed; Sina Kinoush; Salim S Virani
Journal:  Curr Atheroscler Rep       Date:  2021-06-19       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.